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Glossary of terms 
AC Axillary clearance 
AIC Akaike information criterion, a model fit statistic which penalizes for 
the number of dependent variable in a regression model, for a given 
data set the model with the minimum AIC value offer the best fit.    
Bias Is the difference between an estimator's expected value and its true 
value.  
Contralateral Denoting the upper limb opposite to which the condition of interest 
occurs; i.e. in the SNAC trial contralateral specifically refers to the 
non-surgery arm.  
CiVcon Change in volume from baseline at 5 years (unless noted otherwise) 
in the ipsilateral limb 
CiVips Change in volume from baseline at 5 years (unless noted otherwise) 
in the contralateral limb 
δCiV Difference between the CiVips and CiVcontra 
δPCVb The difference in PCVb between the ipsilateral and contralateral limb 
i.i.d. Independent and identically distributed 
Ipsilateral Side of the body where the condition of interest – i.e. tumor cells - 
have been detected. For example, in the SNAC trial ipsilateral limb 
refers to the surgery limb. 
ITT Intention to treat means all patients enrolled and randomly allocated 
to treatment are included in the analysis and analysed as per the 
treatment group they were randomised too.  
MSE Mean squared error of an estimator is the average of the squares of 
the difference between the estimator and what is estimated.  
R2 R-squared or r2, in a regression model R2 indicates the proportion of 
the variance in the dependent variable that is explained by the 
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independent variables.  
Adj. R2 Adjusted R2 is the R2 penalized for the number of dependent 
variable in a regression model. 
RAC Routine axillary clearance 
RCT Randomised controlled trial 
Rho The estimated correlation. 
r.v.’s Random variables 
SNAC Sentinel Node versus Axillary Clearance trial 
SNBM Sentinel node biopsy management 
SNB Sentinel node biopsy  
SSSS SNAC study specific scales 
Vips Volume in the ipsilateral limb at 5 years 
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Preface 
Students Role 
Over the last 3 years I have had involvement to a greater or lesser extent with the 
analysis of the 5 years results for the Sentinel Node versus Axillary Clearance (SNAC) 
trial - The Royal Australasian College of Surgeon’s multicentre randomized controlled 
trial (RCT) comparing sentinel node biopsy management (SNBM) versus routine 
axillary clearance (RAC) in women with clinically node-negative early onset breast 
cancer. In particular over the last year I have collaborated with the principal investigator 
to prepare the analysis for SNAC 5 year results and manuscript which has 
subsequently been published in a peer reviewed clinical journal.  
The pre-specified primary outcome for the SNAC trial was percentage increases in arm 
volume from baseline (PCVb) in the ipsilateral arm (i.e. the arm receiving the surgery). 
The potential exists that a proportion of this change in limb volume would be 
associated with confounding factors such as weight and muscle change over time.  
A novel approach to model the arm swelling which accounts for these potential 
confounding factors and accommodates the differential growth between the arms 
included the contralateral arm (the opposite arm to that receiving surgery) data in the 
assessment of lymphedema. Arm swelling was calculated as PCVb in both the 
ipsilateral and contralateral arm for the 1088 women from the SNAC trial. The 
difference in PCVb between the ipsilateral and contralateral arm (δPCVb) was 
calculated and assumed to be a measure of swelling accounting for confounders, 
differential growth between the arms and other factors (weight gain/loss etc). Analysis 
of the 5 year data included δPCVb as the dependent variable. 
The purpose of this work place project was to build on prior work and explore the 
assumption that the contralateral limb data afforded improvements in modeling 
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lymphedema (arm swelling) and thus allow for a more efficient estimate of the 
treatment effect.  
Of interest was how the assessment of the efficiency of the various models of interest 
was conducted. The efficiency of the various models was estimated via a simulation 
experiment. The results of the simulation experiment suggest that a closer model fit 
(improved efficiency) is garnered via use of both the ipsilateral and contralateral arms 
in the assessment of lymphedema. This finding was corroborated in the SNAC trial 
when comparing models with and without the contralateral limb data.  
Reflections on learning 
As important or significant as this finding is, I believe that it is in the implementation of 
the scientific method where I have gained the most over the course of the work place 
project (WPP). The scientific method implies: a) asking a question i.e. 'which of various 
pre-specified regression models, best models the variability associated with the 
measurement of lymphedema and thus affords the most efficient estimate of the 
treatment effect'; b) designing and running a simulation experiment to assess the 
efficiency of the regression models; c) implementation of the regression model 
identified in the simulation experiment on the SNAC trial data.  
The approach of performing a simulation experiment to ascertain which method to 
pursue in subsequent analysis is one I envisage I will use again. In terms of the 
practicalities of running a simulation experiment, I had no experience of generating 
multivariate normal data previously. Any deficiency here was satisfied by SAS 
documentation courtesy of Wicklin (2013). 
Other than the data simulation, I am familiar with the statistical principles and methods 
implemented in the report. Least squares regression analysis was performed looking at 
the treatment effect at 5 years. Models were unadjusted and adjusted for various 
variables.  
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All statistical analyses (other than graphs) were performed using SAS, version 9.3. 
Graphs were produced in STATA v12.  
Teamwork 
The project was self-guided; no teamwork was required other than regular meetings 
with my supervisor.  
Ethical considerations 
A request to the RACS group was made to use the SNAC data for the purpose of 
conducting a sub-study with the intention to submit to as a WPP. Approval for use of 
the data was formally given at the SNAC trials operations executive committee meeting 
on the 11th of October 2016.  
The completed report was forwarded to the principal investigator of the SNAC trial as a 
matter of courtesy. 
De-identified data was used for all analysis for the WPP. 
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Project Report 
Title 
An assessment and evaluation of alternative methods of modeling lymphedema in the 
SNAC trial. 
Location Dates 
The project was conducted at the NHMRC CTC over semester 2 2016. 
Context 
Between 15% and 20% of breast cancer patients develop lymphedema following breast 
cancer surgery (Petrek et al 2000). Detection of lymphedema - as with the SNAC trial - 
often involves taking the ipsilateral arm volume measurements at baseline and then 
intermittently post-operatively. An issue with restricting the assessment of lymphedema 
to the ipsilateral arm is that the potential exists for a proportion of this change in limb 
volume to be associated with confounding factors such as weight and muscle change 
over time. 
The assumption underlying this work place project is that information afforded by the 
contralateral arm would account for some of the potential confounding factors. The 
purpose of this report then is to assess the impact of inclusion of the contralateral arm 
data on SNAC trial analysis results and to further interrogate the efficiency gains 
afforded by the contralateral arm volume. A simulation experiment was conducted to 
evaluate the efficiency of different estimators. The analysis model which gave the most 
efficient estimate was used to analyse the SNAC trial data. This methodology (the 
simulation experiment) was used, as opposed to performing all possible analyses then 
choosing that which best suits an investigators perception.  
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Student contribution 
Research was undertaken into various aspects of this WPP including that which 
informed an understanding of the issues relating to the detection of lymphedema, 
simulation of multivariate normal distributions, detecting collinearity via eigenvalue 
decomposition and bootstrapping. The latter three methods (simulation, collinearity and 
bootstrapping) were not previously encountered in the Bio-statistics Collaboration of 
Australia.  
Statistical issues 
Statistical issues addressed in this WPP include 1) simulation experiment, 2) Least 
squares regression analysis, 3) Model selection and 4) Assessment of collinearity in 
final regression model. 
Declaration 
I David Espinoza certify that this project is evidence of my own work, with direction and 
assistance provided by my project supervisor. Further this work has not been 
previously submitted for academic credit. 
 
20/06/2017 
David Espinoza Date 
Supervisor Statement  
David has worked independently this semester to complete the report for this 
workplace project. Several meetings throughout the semester occurred where David 
has shown good progress with the development of ideas and statistical methods and in 
the communication of methods and results.  
 20/06/2017 
Val Gebski Date 
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Project Description 
Background 
Lymph nodes are organs which form part of the body’s lymphatic system. The lymph 
nodes play an active role in the immune system but also help determine if cancer cells 
have developed and spread throughout the body. Breast cancer spreads through the 
lymphatic system to lymph nodes close to the cancer site, in most likely for breast 
cancer to the lymph nodes located in the axilla, or armpit area. 
The use of axillary clearance (AC) - removal of lymph nodes from the arm pit - for the 
detection of tumor cells carries the potential for risks and complications including but 
not limited to lymphedema. Lymphedema is long term severe arm swelling caused by 
damage to the lymphatic system. An interruption or blockage in the lymphatic system 
causes lymph fluid to build up in subcutaneous tissue in the arm. Women with 
lymphedema resulting from 'breast cancer therapy can experience a substantial degree 
of functional impairment and psychological morbidity and diminished quality of life' 
(Erickson 2001: 96). 
The first lymph node which cancer cells are most likely to spread is defined as the 
sentinel lymph node. Sentinel-lymph-node biopsy management (SNBM) is a procedure 
where the identified sentinel node is removed and examined for the presence of cancer 
cells. The results of the biopsy guide the management of the cancer. In general SNBM 
avoids the use of an AC in the cases where no metastasis has been detected in the 
sentinel node thus minimising side effects and morbidity with a more invasive 
procedure.  
The Royal Australasian College of Surgeon’s Sentinel Node versus Axillary Clearance 
(SNAC) trial is a multicentre randomised controlled trial (RCT) comparing sentinel node 
biopsy management (SNBM) versus routine axillary clearance (RAC) in women with 
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clinically node-negative early onset breast cancer. 544 women were randomised to 
RAC (sentinel lymph-node biopsy followed by immediate AC) while 544 women were 
randomised to SNBM (sentinel lymph-node biopsy followed by an AC if the sentinel 
lymph-node was deemed positive or if the sentinel lymph-node could not be detected). 
Women assigned to SNBM which returned positive cancer results from the 
histopathology were required to return for an AC at a later date.  
The objective of the SNAC trial was to determine if sentinel node biopsy (and axillary 
clearance in node positive patients) resulted in less morbidity compared to RAC.  
Quantitative measures collected by the SNAC trial included evaluations of shoulder 
function, arm volume for both the ipsilateral and contralateral arms and patients’ arm 
morbidity self-assessed via a SNAC Study Specific Scale quality of life questionnaire. 
Arm volume was estimated using the formula for a truncated cone 
V=
100
12π
(Ca
2
+Cb
2
+C a
2∗C b
2
)
 
where Ca and Cb are the apex and base circumference of the cone. Each cone was 
defined as the arm circumference measured at 10cm intervals commencing from the tip 
of the middle finger and proceeding upwards along the arm. The total volume for each 
arm is obtained by summing the volumes of 5 truncated cones.  
Assessments were carried out at baseline, 6months, 12 months and then yearly until 5 
years. 
The SNAC pre-specified primary outcome was percentage increases in arm volume 
from baseline (PCVb) in the ipsilateral arm (Gill et al, 2009). Secondary endpoints were 
the proportion of women with an increase in PCVb of greater than 15% and changes in 
SNAC study specific scales (SSSS) score from baseline. The cut-point of 15% was 
assumed to indicate the presence of lymphedema.  
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The potential exists that a proportion of the PCVb to be associated with confounding 
factors such as weight and muscle change over time. Various methods have been 
suggested to tease out the impact of these factors in the measurement of lymphedema 
and thus enable assessment of the treatment effect which is more representative. 
There is no agreed method for the detection of arm swelling (Petrek et al, 2000). 
Aim 
The assumption underlying this work place project is that information afforded by the 
contralateral arm would account for some of the potential confounding factors 
associated with lymphedema. The broad research objective of the work place project 
was then to determine how inclusion of the contralateral arm data in the assessment of 
lymphedema would impact the analysis results in the SNAC trial. 
The proposed work place project was broken up into two parts. 
Part 1: Simulation Study 
A simulation experiment was conducted to evaluate the efficiency of 6 pre-specified 
regression models designed to model lymphedema. The primary hypothesis of the 
simulation experiment was that inclusion of the contralateral arm volume in regression 
models will improve the efficiency of the estimate of the treatment effect. 
Recall that the objective of the SNAC trial was to determine if treatment, SNBM 
compared to RAC resulted in reduced arm swelling and thus less morbidity. An efficient 
(stable, consistent) estimate of lymphedema would thus afford a more precise estimate 
of the effect of treatment on lymphedema in the SNAC trial. 
Part 2: Analysis of lymphedema in SNAC study 
Using the most efficient analysis method identified by the simulation experiment in part 
1 of the work place project the treatment effect on lymphedema was estimated in the 
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SNAC trial. Additionally an assessment of the gain in information afforded by inclusion 
of the contralateral limb data was conducted. 
Methods  
Part 1: simulation study.  
Development of a population model:  
Descriptive analysis of the SNAC ipsilateral and contralateral arm volumes was 
undertaken. The analysis was conducted by treatment groups SNBM and RAC for both 
the intention to treat cohort and for the subgroup of women with a negative SNB at 
baseline.   
The ipsilateral and contralateral arm volumes at baseline and at 5 years were 
summarised as mean and variance. Covariance between arm volume (ipsilateral and 
contralateral) over baseline and 5 years were presented. The degree of relationship 
between and within arm volumes and over time was assessed via Pearson correlation. 
Confidence intervals for the correlation coefficient were estimated via use of Fisher’s z-
transformation and via the percentile bootstrapped method.   
Mean arm volume over time for the ipsilateral and contralateral limb were graphed by 
allocated treatment for both the intention to treat cohort and for women with a negative 
SNB at baseline. A histogram was used to depict the distribution of the ipsilateral and 
contralateral arm volume at baseline. 
A population model for arm volume changes associated with breast cancer surgery was 
developed guided by descriptive analysis of the SNAC trial data. Hypothesized factors 
affecting arm volume over time were: 
 general changes in weight and muscle  
 allocated treatment group 
 baseline SNB status 
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Based on the descriptive analysis the simulated data used in the simulation experiment 
was generated as a multivariate normal.  
Recall that women randomised to the SNBM group which had a positive SNB or if the 
sentinel node could not be detected had a subsequent AC. To replicate the design of 
the SNAC trial if subject 'i' was allocated to the RAC group or if they were randomly 
selected (with probability π) as having a positive SNB at baseline, then the population 
parameters (mean vector and covariance matrix) were given by those of the RAC 
group. 
Simulating normal distributions 
The multivariate normal data was generated via the SAS RANDNORMAL function. The 
RANDNORMAL function generates random multivariate normal distributions by 
transforming independent and identically distributed (i.i.d.) standard normal random 
variables (r.v.’s).  
To generate independent standard normal r.v.’s the Box-Muller method is used; i.e. if U1 
and U2 are i.i.d. uniform(0,1) random variables then  
  
Z1 =cos (2 πU 2) log (
1
U 1 )
1/2
Z2 =sin (2 π U 2) log (
1
U 1 )
1 /2
 
are i.i.d N(0,1). A d-dimensional multivariate normal with mean vector μ and covariance 
matrix Σ is generated by first generating i.i.d standard normals say z=(z1, z2, z3, …, zd ), 
then the transformation of the i.i.d standard normals  X = T T z + μ is distributed as a 
Nd(μ, Σ) (Gentle, 2003). The element T is such that T 
T T = Σ i.e. the Cholesky 
decomposition of the covariance matrix Σ. 
Regression models and the simulation experiment 
Regression Models to be assessed are: 
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 Ipsilateral arm volume (Vips) at 5 years adjusted for treatment, 
 Vips adjusted for treatment and baseline ipsilateral arm volume, 
 Changes in arm volume between baseline and 5yrs in the ipsilateral arm (CiVips) 
adjusted for treatment, 
 CiVips adjusted for treatment & baseline volume in the ipsilateral arm; 
 CiVips adjusted for treatment & change in volume in the contralateral arm 
(CiVcon), 
 Difference in the CiV between the ipsilateral and contralateral arm (δCiV) 
adjusted for treatment. 
 
A simulation experiment of 1000 simulations of the SNAC data of sample size N=1000 
was conducted to determine which of the 6 prespecified models would best account for 
the inherent variability in the data and, thus afford an efficient estimate of the treatment 
effect.  
For the various models considered Least squares regression analysis was conducted 
to estimate the mean treatment effect; bias the difference between an estimator's 
expected value and its true value; mean square error (MSE) the average of the 
squares of the difference between the estimator and what is estimated; Akaike 
information criterion (AIC) a relative measure of goodness of fit which penalizes for 
number of dependent variables (for the given dataset the preferred model is one with 
the minimum AIC value); R2 which measures the proportion of the variance in the 
dependent variable and the adjusted R2 which includes a penalty for the number of 
dependent.  
The MSE is the primary measure of efficiency used to compare the 6 prespecified 
models. Note that the MSE can also be obtained as the sum of the variance of an 
estimator plus the square of its bias. The MSE then has two components, one a 
measure of the precision/variability of the estimator and the other a measure of the 
accuracy/bias of the estimator. The model then with minimum MSE was deemed to 
offer the most efficient estimate while controlling for bias. 
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The simulation experiment was further conducted under several scenarios to assess 
their impact on the prespecified models. Scenarios investigated: 1) when there is no 
treatment effect (none, some and substantial), 2) changing the proportion with positive 
SNB at baseline, 3) changing the randomisation allocation ratio (1:1 and 2:1) and, 4) 
changing the correlation between the variables. 
Under the assumption that the arm volumes are normally distributed and noting that 
differences of normal random variables are normal it follows that CiV and δCiV are 
normal. Lumley et al (2002) show that in public health research regression parameters 
for t-test and least-squares linear regression are valid for modest sample sizes where 
modest is often fewer than 100. The simulated data and the SNAC data population size 
was ~1000 thus the normality of the residuals of the proposed simple and multivariate 
linear regression models was assumed. 
The simulated treatment effect 
Turning our attention to model 1, a regression model for Vips at 5 years adjusted for 
treatment can be written as 
V ips=β0+ β1 X t + ϵ  
where Vips  is a n*1 vector of the ipsilateral arm volumes at 5 years, β0 and β1 are the 
regression coefficients which are to be estimated, Xt is a n*1 vector of 1's and 0's  
designating the allocated treatment arm (1=SNBM and 0=RAC) and lastly ϵ is a n*1 
vector of standard normally errors.  
Taking expectation of both sides of the regression equation above and setting Xt to be 
equal to '1' or '0' we have 
E (V ips | X t=1)=β0+ β1  
and 
E (V ips | X t=0)=β0  
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Subtracting the second equation from the first gives β1, the regression coefficient for 
the treatment effect 
β1 = E (V ips |X t=1)− E (V ips | X t=0)  
Recall that the mean vector and covariance matrix for the SNBM group was randomly 
given with probability π by that of the RAC group if they were designated as having a 
positive SNB at baseline. By taking the sum of the expectation of ipsilateral arm volume 
in the SNBM group (i.e. Vips given Xt=1) over the disjoint union of the events, SNB 
positive (Sn=1) and SNB negative (Sn=0); the expected 5 year volume for the ipsilateral 
limb in the SNBM group is then 
E (V ips | X t=1)
= E(V ips | X t=1, S n=1) P (S n=1) + E (V ips | X t=1, S n=0) P (S n=0)
= E(V ips | X t=1, S n=1) π + E (V ips | X t=1, S n=0) (1−π)  
Thus for β1, the treatment effect we have  
E (V ips| X t=1) − E (V ips | X t=0)
= E(V ips | X t=1, S n=1) π + E (V ips | X t=1, S n=0) (1−π)−E (V ips |X t=0)
= E (V ips | X t=1, Sn=0) (1−π) − E (V ips| X t=0)+ E (V ips |X t=1, S n=1) π  
Now as the 5 year arm volume in the SNBM group given a positive SNB is the same as 
that of the RAC group, we have 
E (V ips | X t=1, S n = 1)= E (V ips | X t=0)  
the regression coefficient for the treatment effect β1 reduces to 
E (V ips| X t=1, S n=0) (1−π)− E (V ips | X t=0) (1−π)
= [ E (V ips |X t=1, S n=0) − E (V ips | X t=0)] (1 −π)  
That is, the true treatment effect is weighted by the probability of a negative sentinel 
node (1-π). Denote the difference in the 5 year ipsilateral arm volume between the 
RAC group and the SNBM group given a negative SNB as μ, then we have β1 = μ (1-
π).  
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Similarly derivation of the treatment effect for the 6 pre-specified models gives the 
treatment effect as β1 = μ (1-π) (see appendix for details). 
Part 2: Analysis of lymphedema in SNAC study 
The treatment effect on lymphedema was estimated in the SNAC trial using the most 
efficient regression model identified by the simulation experiment conducted in part 1 of 
this project. Descriptive statistics of baseline potential risk factors which may influence 
arm volumes presented, mean (SD) for continuous factors and N (%) for categorical 
variables.  Univariate least squares regression analysis was conducted to identify 
potential risk factors of lymphedema. A multivariate model was developed based on 
backwards selection procedure. For the purpose of model selection, potential risk 
factors found to be univariately associated with lymphedema at or below a p-value of 
0.2 were included in the full risk set. The conservative level of 0.2 was used to ensure 
no important factors were excluded from the full analysis risk set. Backwards selection 
was conducted on the full risk set to identify the parsimonious model.  
The treatment effect was assessed univariately and when adjusted. The MSE, AIC and 
adj. R2 were used to assess the efficiency gains in the estimate of the treatment effect 
that the contralateral limb data affords. 
Data Management 
The first and last randomisation for the SNAC study occurred in May 2001 and May 
2006. The SNAC one year and 3 year trial results (Wetzig 2015) have previously been 
published. The 5 year results have been reported and submitted to a journal for 
publication. Analysis for the WPP used data from the SNAC trial which has been 
previously analysed. As such the required data cleaning/manipulation for the purpose 
of this WPP was omitted. 
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In the WPP the issues of missing data where not addressed. This project focuses on 
the impact of different sources of information (contralateral limb data) on potential 
analysis results. 
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Results  
Part 1: simulation study.  
Descriptive analysis of the SNAC data 
Figures 1 and 2 depict arm volume in the ipsilateral and contralateral arms over time 
(i.e. at baseline, 1, 6 and 12 months then yearly until 5 years) for both the intention to 
treat (ITT) population and the sentinel node biopsy (SNB) negative subgroup.  
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Figure 2: Mean Arm volume over time
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Arm volume for the SNAC ITT cohort increases from baseline in both the ipsilateral and 
contralateral limbs and was sustained for the duration of the trial (Figure 1). Over time 
there appears to be little or no difference in the contralateral limb volume between the 
allocated treatment groups. The ipsilateral arm volume was greater in magnitude in the 
RAC group compared to the SNBM group for the duration of the trial. 
Table 1: SNAC Baseline sentinel node biopsy status 
 N +ve -ve 
RAC 531 168 363 
SNBM 538 182 356 
total 1069 350 719 
 
The distribution of SNB status at baseline is given in Table 1. At baseline, 34% 
(182/538) of the SNBM group were found to have a positive SNB. As specified in the 
protocol these women had an immediate AC. The arm volume over time for patients 
that have a negative SNB at baseline (Figure 2) show similar arm patterns as that for 
the ITT cohort (Figure 1), though the magnitude of the arm volume increase was 
smaller in both the ipsilateral and contralateral limb. 
Distribution of arm volumes at baseline in the SNAC study 
The distribution of the arm volume in both the contralateral and ipsilateral arms at 
baseline is represented in Figure 3. The histograms of arm volumes at baseline have a 
symmetric distribution. The overlaid normal density curves suggest that arm volumes at 
baseline are normally distributed. SNAC baseline arm volume mean (standard 
deviation) for the ipsilateral arm is 2.45L (0.57L) while that of the contralateral arm is 
2.45L (0.57L). Arm volumes for both the ipsilateral and contralateral arms are normally 
distributed with mean 2.45L and standard deviation 0.57L. 
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The Pearson correlation 'between' the ipsilateral and contralateral arms at baseline and 
at 5 years is given in Table 2. As expected the SNAC data show a high level of 
correlation between an individual’s ipsilateral and contralateral arm volume at both 
baseline and at 5 years (0.98 and 0.95 respectively).Similarly the correlation 'within' the 
ipsilateral and 'within' the contralateral arms between baseline and 5 year show a high 
level of correlation (0.88 and 0.87 respectively).  Confidence intervals for the 
correlation coefficient where estimated via use of Fisher’s z-transformation and via the 
percentile bootstrapped method. Both estimates agree. 
Table 2: SNAC arm volume correlation and 95% CI  
 Rho 95% CI’s 
Ipsilateral and Contralateral limb (between) 
Baseline 0.98 (0.97 ,0.98) 
5 year 0.95 (0.95 ,0.96) 
Baseline and 5 year (within) 
Contralateral 0.88 (0.87 ,0.90) 
Ipsilateral 0.87 (0.85 ,0.89) 
Note: 
1. Ipsilateral and contralateral arm volume Pearson correlations presented. 
2. The 95% CI presented where calculated via: a. Fisher's z-transformation, b. percentile 
bootstrapped method. Note these CI concur to 2 decimal places. 
3. The bootstrapped 95% CI based on 1000 repeated samples of the data; sampling with 
replacement was conducted. 
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Figure 3: Histogram arm volume at baseline
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4. Rho is the estimated correlation. 
 
The mean vector and covariance matrix for arm volumes for the SNAC data is given in 
Table 3 for both the ITT population and the SNB positive and negative subgroups. Both 
the ITT population and the SNB status subgroups mean arm volumes increase in the 
respective arms over the course of the study (baseline to 5 years). As previously 
observed the magnitude of the increase in arm volume is smallest within the SNB 
negative subgroup while the largest change occurs for the SNB positive subgroup. 
Table 3: SNAC Mean vector and covariance matrix of arm volumes at baseline and 5 years,  
By allocated treatment – ITT population 
 RAC SNBM 
  Cov: baseline Cov: year 5  Cov: baseline Cov: year 5 
 mean Ipsi. Cont. Ipsi. Cont. mean Ipsi. Cont. Ipsi. Cont. 
Ipsilateral baseline 2.46 0.32    2.44 0.32    
Contralateral baseline 2.45 0.31 0.33   2.44 0.32 0.35   
Ipsilateral year 5 2.59 0.29 0.28 0.41  2.56 0.30 0.29 0.38  
Contralateral years 5 2.52 0.26 0.26 0.34 0.32 2.53 0.29 0.29 0.36 0.36 
By SNB status at baseline 
 SNB positive SNB negative 
  Cov: baseline Rho: year 5  Cov: baseline Cov: year 5 
 mean Ipsi. Cont. Ipsi. Cont. mean Ipsi. Cont. Ipsi. Cont. 
Ipsilateral baseline 2.50 0.37    2.43 0.30    
Contralateral baseline 2.50 0.37 0.39   2.41 0.29 0.32   
Ipsilateral year 5 2.68 0.32 0.31 0.47  2.53 0.28 0.27 0.35  
Contralateral years 5 2.59 0.29 0.29 0.39 0.37 2.50 0.26 0.26 0.26 0.37 
Note: 
1. Ipsi. and Cont. refer to ipsilateral and contralateral respectively. 
2. Cov denotes covariance. 
 
Population model, the simulated multivariate normal parameters: 
Baseline and 5 year ipsilateral and contralateral arm volumes were simulated as 
multivariate normal where mean vectors and covariance matrices were defined for the 
simulated treatment groups - RAC and SNBM group - as follows: 
Table 4: Simulated multivariate mean vector and covariance matrix 
 RAC SNBM 
  Cov.: baseline Rho: year 5  Cov.: baseline Rho: year 5 
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 mean Ipsi. Cont. Ipsi. Cont. mean Ipsi. Cont. Ipsi. Cont. 
Ipsilateral baseline 2.45 0.32    2.45 0.32    
Contralateral baseline 2.45 0.31 0.33   2.45 0.32 0.35   
Ipsilateral year 5 2.59 0.29 0.28 0.41  2.56 0.30 0.29 0.38  
Contralateral years 5 2.53 0.26 0.26 0.34 0.32 2.53 0.29 0.29 0.36 0.36 
Note: 
1. Ipsi. and Cont. refer to ipsilateral and contralateral respectively. 
2. Cov. denotes covariance. 
3. If subject 'i' was allocated to the RAC group or if they were randomly selected (with 
probability π=0.3) as having a positive SNB at baseline, then the mean vector and 
covariance matrix were given by those of the RAC group. 
 
The simulation experiment 
The average estimated treatment effect, bias, adjusted R2, MSE and AIC for the 
various models of interest are presented in Table 5. Model 2 and 5 have the highest 
adjusted R2 of 0.688 and 0.678 respectively indicating that ~32% of the variability in the 
dependent variable (Vips or CiVips) is unaccounted for, in either model. Compared to the 
other models an adjusted R2 of .678 represents a 38 (=0.678/0.018) fold improvement 
over the next highest adjusted R2 value of 0.018 (model 4). Model 5 has the smallest 
MSE (0.040) followed closely by model 6 (0.045). Model 5 offers a .3 to .1 fold 
improvement in MSE over models 1 to 4. The treatment estimated effect (βtreat) concurs 
with the true treatment (µ) to 3 decimal places for models 2 to 6. The estimated bias, 
the difference between the estimated treatment (βtreat) and true treatment (µ) offer little 
to differentiate the models. Model 5 has the smallest AIC; indicating that for the 
simulated data, on average model 5 - relative to the other models - offers the best fit 
while still accounting for number of covariates in the model.  
Table 5: Model fit statistics 
Model βtreat (SD) bias MSE Adj. R
2
 AIC   Model description 
1 -0.029 (0.040) -0.000 0.395 0.001 -929   Vips adjusted for treatment 
2 -0.030 (0.022) -0.001 0.123 0.688 -2094   Model 1 + baseline ipsi. arm volume 
3 -0.030 (0.022) -0.001 0.125 0.002 -2079   CiVips adjusted for treatment 
4 -0.030 (0.022) -0.001 0.123 0.018 -2094   Model 3 + baseline ipsi. arm volume 
5 -0.030 (0.013) -0.001 0.040 0.678 -3212   Model 3 + CiVcon 
6 -0.030 (0.014) -0.001 0.045 0.005 -3100   δCiV adjusted for treatment 
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Note: 
1. Model parameters: µ=-0.03, π=0.3, 1:1 Treatment allocation. 
2. Fit statistics based on 1000 simulations of data (sample size 1000). 
 
 
In general under the various scenarios conducted (µ ϵ [-0.06, -0.03, 0.00], π ϵ [0.1, 0.3, 
0.5], and 1:1 or 2:1 Treatment allocation, refer to appendix Table 11) model 5 accounts 
for more variability in the dependent variable than the other models (maximises R2), 
has the lowest MSE thus offering the most efficient estimate of the treatment effect 
while controlling for bias and further offers the best fit (smallest AIC).  
Summary for the simulation experiment 
Based on the MSE, model 5 (CiV in the ipsilateral arm at 5 years adjusted for treatment 
and CiV in the contralateral arm) was deemed to offer the most efficient estimate of the 
treatment effect and further offered the best fit and thus selected for all subsequent 
analysis. 
Part 2: Analysis of lymphedema in SNAC study 
Baseline factors (descriptive statistics) 
Baseline descriptive statistics of potential factors which may influence arm volumes is 
given in Table 6. Other than the variable '15+ nodes removed in AC and SNB' all other 
prognostic factors are well balanced between the allocated treatment groups (SNBM 
and RAC). Balance was not expected in the variable '15+ nodes removed in AC and 
SNB' as fewer node samples were expected in the SNBM group. 
Table 6: SNAC Baseline descriptive statistics 
Factors Level 
SNBM 
(N=544) 
RAC 
(N=544) 
CiV contralateral arm: mean(SD)  0.06 (0.27) 0.06 (0.28) 
WHO Performance Status 1 32 (6%) 25 (5%) 
Tumour Palpable Yes 309 (57%) 309 (57%) 
Other major concurrent illness Yes 238 (44%) 228 (42%) 
Diabetes Yes 33 (6%) 31 (6%) 
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Factors Level 
SNBM 
(N=544) 
RAC 
(N=544) 
Hypertension Yes 123 (23%) 111 (21%) 
Other illness (not diab. or hyper.) Yes 154 (29%) 158 (29%) 
Age: mean(SD)  57.9 (10.3) 58.3 (10.1) 
Age 50+ Yes 425 (78%) 424 (78%) 
Weight: mean(SD)  73.2 (16.1) 72.9 (15.0) 
Height: mean(SD)  161.8 (6.8) 162.0 (6.8) 
BMI: mean(SD)  27.9 (5.8) 27.9 (5.8) 
Overweight or Obese Yes 332 (65%) 320 (64%) 
% weight change from baseline: mean(SD)  2.0 (9.2) 1.8 (9.6) 
Infection before 30 days Yes 48 (9%) 73 (13%) 
Did patient get adjuvant endocrine therapy Yes 372 (68%) 367 (67%) 
Did patient get adjuvant chemotherapy Yes 169 (31%) 164 (30%) 
15+ nodes removed in AC and SNB Yes 91 (17%) 276 (51%) 
SNB negative Yes 356 (66%) 363 (68%) 
Note: N (%) shown unless indicated otherwise. 
 
Univariate analysis at 5 year visit   
Of the 19 potential risk factors in Table 6 only 9 factors were found to be independently 
associated with CiVips (Table 7).  
Table 7: SNAC univariate analysis at 5 years - factors predicting CiV in the ipsilateral arm  
Factor Estimate SE 95% CI P-value 
Treatment (SNBM V RAC) -0.042 0.021 (-0.08 to -0.00) 0.050 
CiV contralateral limb 0.906 0.024 (0.86 to 0.95) <.001 
WHO Performance Status (1 v 0) -0.065 0.049 (-0.16 to 0.03) 0.185 
Tumour Palpable (Yes v No) 0.013 0.022 (-0.03 to 0.06) 0.536 
Other major concurrent illness (Yes v No) 0.075 0.022 (0.03 to 0.12) <.001 
Diabetes (Yes v No) 0.042 0.048 (-0.05 to 0.14) 0.383 
Hypertension (Yes v No) -0.014 0.026 (-0.07 to 0.04) 0.590 
Other illness* (Yes v No) 0.075 0.024 (0.03 to 0.12) 0.002 
Age -0.007 0.001 (-0.01 to -0.00) <.001 
Age 50+  (Yes v No) -0.127 0.026 (-0.18 to -0.08) <.001 
Weight 0.000 0.001 (-0.00 to 0.00) 0.493 
Height -0.001 0.002 (-0.00 to 0.00) 0.436 
BMI 0.001 0.002 (-0.00 to 0.00) 0.617 
Overweight or Obese  (Yes v No) -0.002 0.023 (-0.05 to 0.04) 0.921 
% weight change from baseline 0.020 0.001 (0.02 to 0.02) <.001 
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Factor Estimate SE 95% CI P-value 
Infection before 30 days 0.017 0.036 (-0.05 to 0.09) 0.643 
Did patient get adjuvant endocrine therapy(Yes v No) -0.008 0.023 (-0.05 to 0.04) 0.716 
Did patient get adjuvant chemotherapy (Yes v No) 0.062 0.023 (0.02 to 0.11) 0.008 
15+ nodes removed in AC + SNB (Yes v No) 0.048 0.023 (0.00 to 0.09) 0.032 
SNB negative (Yes v No) -0.064 0.023 (-0.11 to -0.02) 0.006 
Note: * Other illness excludes diabetes and hypertension 
 
As noted previously prognostic factors found to be associated independently with CiVips 
at a conservative p-value of 0.2 or smaller were considered for inclusion in the full risk 
set for model selection purposes. Factors included in the full risk set include: ‘WHO 
performance status’, ‘Other major concurrent illness’, ‘Other illness (not diabetes or 
hypertension)’, ‘Age 50+’, '% weight gain from baseline', ‘Did patient get adjuvant 
chemotherapy’, ‘15+ nodes removed in AC and SNB’, ‘SNB status’, ‘allocated 
treatment’ and ‘CiVcon’. 
Model selection, the parsimonious model 
Model selection was based on the backwards elimination process.  
Of the 6 prespecified models, model 5 (the CiV in the ipsilateral arm at 5 years 
adjusted for treatment and CiV in the contralateral arm) was identified in the simulation 
experiment as offering the best fit and the most efficient estimator of the treatment 
effect. As such ‘allocated treatment’ and ‘CiVcon’ were not included in the risk set as 
they were to be included in the final model irrespective of whether or not they added 
anything to the model. A sensitivity analysis was conducted which included ‘allocated 
treatment’ and ‘CiVcon’ in the risk set. In both instance the variables retained in the final 
model were ‘allocated treatment’ and ‘CiVcon’, ‘SNB status’, 'Other major concurrent 
illness’ and '% weight gain from baseline' (Table 8).   
Table 8: Factors which remain significant in a multivariate analysis (backwards selection). 
Parameter Estimate 95% CI p-value 
Intercept 0.131 (0.085, 0.176) <.0001 
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Parameter Estimate 95% CI p-value 
CiV contralateral limb 0.792 (0.729, 0.856) <.0001 
Treatment (SNBM) -0.042 (-0.068, -0.017) 0.0010 
SNB negative (Yes)  -0.061 (-0.088, -0.034) <.0001 
Other major concurrent illness (Yes) 0.054 (0.028, 0.080) <.0001 
% weight change from baseline 0.004 (0.003, 0.006) <.0001 
 
Women in the SNBM group had on average a 0.04L (95% CI: 0.07 to 0.02) reduction in 
CiVips compared to women in the RAC group. Of the other factors in the parsimonious 
model ‘CiVcon’ had the largest effect on CiVips at 5 years. A 1L increase in CiVcon’ 
resulted in an increase in CiVips of 0.79L (95% CI: 0.73 to 0.86). While compared to 
women who do not report an 'Other major concurrent illness’ at baseline those that do 
have an average increase in CiVips of 0.05L (95% CI: 0.03 to 0.08). A negative SNB at 
baseline results on average with a 0.06L (95% CI: 0.09 to 0.03) reduction in CiVips 
compared to women with a positive SNB. For a unit increase in '% weight change from 
baseline' CiVips increases on average by 0.004L (95% CI: 0.0003 to 0.006). 
Diagnostic plots (see appendix) indicate the residuals are plausible normally 
distributed. Four percent of studentized residuals were found to be greater than ±2. Of 
the fitted values 57/781 cases had a high leverage (leverage > 2*number of 
parameters/n) indicating some concern for the potential for outliers to influence 
analysis. Only 1 case of all fitted values had a Cook's distance measures of greater 
than 20% while only 3 cases had a measure greater than 10% implying only minor 
concern, if any, about the influence of outliers on the fit of the regression function.  
The treatment effect and assessment of the efficiency of various models 
Table 9 presents the estimated coefficients, p-value, adjusted R2, MSE and the AIC for 
various models. In particular model a. and b. show univariate analysis of allocated 
treatment and CiVcon respectively against the dependent variable. Model e. shows the 
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parsimonious model while model d. shows the effect of removing CiVcon from model e. 
The dependent variable in each model is CiVips.  
Table 9: Parameter estimates, R
2
 and MSE for various models. 
Model Parameter Estimate 95% CI p-value 
Adj. 
R
2
 MSE AIC 
a. Intercept 0.172 (0.106, 0.238) <.0001 0.003 0.095 -1833 
 Treatment (SNBM) -0.042 (-0.084, 0.000) 0.0506    
b. Intercept 0.054 (0.041, 0.067) <.0001 0.639 0.035 -2627 
 CiV contralateral limb 0.906 (0.860, 0.953) <.0001    
c. Intercept 0.119 (0.080, 0.159) <.0001 0.644 0.034 -2633 
 Treatment (SNBM) -0.044 (-0.069, -0.019) 0.0007    
 CiV contralateral limb 0.906 (0.860 0.952) <.0001    
d. Intercept 0.131 (0.071, 0.190) <.0001 0.405 0.057 -2233 
 Treatment (SNBM) -0.047 (-0.081, -0.014) 0.0056    
 SNB negative (Yes)  -0.059 (-0.095, -0.023) 0.0013    
 Other major concurrent illness (Yes) 0.106 (0.072, 0.140) <.0001    
 % weight change from baseline 0.020 (0.019, 0.022) <.0001    
e. Intercept 0.131 (0.085, 0.176) <.0001 0.664 0.032 -2678 
 Treatment (SNBM) -0.042 (-0.068, -0.017) 0.0010    
 CiV contralateral limb 0.792 (0.729, 0.856) <.0001    
 SNB negative (Yes)  -0.061 (-0.088, -0.034) <.0001    
 Other major concurrent illness (Yes) 0.054 (0.028, 0.080) <.0001    
 % weight change from baseline 0.004 (0.003, 0.006) <.0001    
 
A simple linear regression of the dependent variable allocated treatment against the 
independent variable CiVips (model a) reveals that univariately treatment is not 
associated with CiVips. On average, compared to the RAC group the SNBM group have 
a 0.042L reduction in CiVips, the 95% CI indicates that this reduction could be as high 
as 0.084L or as little as 0.0L. When CiVcon is added to treatment alone (model c), the 
strength of this association is increased where compared to the RAC group the SNBM 
group have a 0.044L (95% CI: 0.069 to 0.019, p=0.0007) reduction in CiVips. In the 
parsimonious model (model e), allocated treatment is still found to be associated with 
CiVips. In this instance the estimate of the treatment effect is the same as that of the 
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univariate analysis 0.042L (95% CI: 0.068 to 0.017) but the 95% confidence interval for 
this estimate has been reduced.  
Looking at the MSE for models a. to e. (Table 9) we observe that model a. (univariate 
analysis of treatment against CiVips) has the highest MSE (0.095) while model e. (the 
parsimonious model) has the lowest (0.032). Model e. represents ~.3 fold improvement 
in the MSE over model a, 0.5 fold improvement over model d and, 0.91 and 0.94 fold 
improvement over models b and c respectively.  
Univariate analysis of treatment against CiVips (model a) has an adj. R
2 of 0.003 
indicating that more than 99% of the variability in the model is unaccounted for by 
treatment alone. When CiVcon is added to the treatment alone (model b), the estimated 
adj. R2 is 64%, an improvement in the adj. R2 of over 60% over model a. For the 
parsimonious model (model e) the adj. R2 value is 0.66 indicating that 33% of the 
variability is unaccounted for by the model. Model e only offer only a 1.03 fold 
improvement over model b in adj. R2, implying that the majority of the variability in the 
model is explained by CiVcon. The addition of CiVcon to model d results in model e; the 
improvement in adj. R2 as a result of adding CiVcon to model d. is 26% representing a 
1.6 fold improvement in adj. R2.  
The additively of the R2 indicates that the covariates are uncorrelated to each other. For 
models d and e (0.635+0.410 ≠ 0.666) we cannot conclude that the covariates are 
uncorrelated to each other.  
An analysis of the collinearity of the dependent variables in model e is presented in 
Table 10. Draper et al (1998) suggest that a condition number of 30 or more is 
conventionally considered to indicate moderate to severe collinearity. In this instance 
the largest condition number observed is (3.35/0.04739)1/2 = 8.4 indicating low (or no) 
concern for collinearity. Note though that 'CiVcon' and '% Weight change' have large 
variance proportions (greater than 50%) though their condition index is only 3.4 thus 
representing only a slight concern for collinearity. 
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Of all models considered (Table 9) model e has the smallest AIC. In terms of the AIC, 
MSE and R2 value model e. offer the best fit to the data. 
Table 10: Collinearity diagnostics for model e. treatment and the CiVcont added to the 
parsimonious model 
# Eigenvalue 
 
Condition 
Index 
Proportion of Variation 
 
Intercept SNB -ve 
Other... 
illness  
% Weight  
change Treatment CiVcont 
1 3.35  1 0.00628 0.02137 0.02788 0.00552 0.00781 0.00671 
2 1.55016  1.46983 9.3*10-4 0.00439 0.00911 0.15080 0.00124 0.14321 
3 0.52620  2.52277 0.00501 0.07380 0.77114 0.02837 0.00771 0.04803 
4 0.28850  3.40710 7.8*10
-4
 0.11450 0.08422 0.71788 0.00384 0.72979 
5 0.23881  3.74483 0.03121 0.69121 0.09303 0.09659 0.11365 0.07225 
6 0.04739  8.40644 0.95579 0.09474 0.01462 8.4*10
-4
 0.86575 1.4*10
-5 
 
Conclusion: 
The primary aim of the report was to discern whether the inclusion of the contralateral 
arm volume added efficiency gains to the regression models designed to detect 
lymphedema and thus enable improvements in the estimate of the treatment effect. 
From the simulation experiment and analysis of the SNAC data we observed that 
inclusion of the contralateral limb data decreases the residual variability in regression 
models. Further, inclusion of the contralateral limb data reduces MSE thus offering 
more accurate estimates of regression parameters while controlling for bias. These 
results then support the hypothesis that inclusion of the contralateral limb data helps 
account for confounding factors such as weight and muscle change over time and thus 
potentially offer more accurate and efficient regression estimates.  
The univariate analysis of the SNAC data suggests that SNBM offers little or no benefit 
over RAC at 5 years. However, the efficiency gains in the treatment estimate resulting 
from the addition of the contralateral limb data to regression models lead to 
conclusions which supports the hypothesis that sentinel node biopsy (and axillary 
clearance in node positive patients) results in less morbidity compared to RAC. 
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Therefore, upon adjusting for potential confounding factors such as weight and muscle 
change over time, we have demonstrated that SNBM offers a clear advantage over 
RAC alone.  
It is interesting to note how the conclusion of a RCT can be affected by specification of 
the analysis of the primary outcome. If the pre-specified analysis or primary outcome of 
the SNAC trial had been a simple linear regression (or t-test) of CiVips the trial 
conclusion would have been negative. Alternatively if the pre-specified analysis had 
included appropriate adjustment of confounding factors the conclusion would be other. 
It is clear then, for a well-run RCT the primary outcome and the statistical methods that 
will be used should be pre-specified. In order to do this a high level of understanding of 
the mechanisms that will modify outcomes need to be understood. In some instances 
this may not be possible; it is in these situations that a well-run simulation experiment 
comes into its own. 
 
  
29 
 
APPENDIX: 
Derivation of the treatment effect for the simulated data.  
The following gives the derivation of the treatment effect for the 6 pre-specified models. 
To facilitate the derivation population parameters where used as specified in Table 4. 
Let: 
 Vips  be a n*1 vector of the ipsilateral arm volumes at 5 years,  
 CiVips  be a n*1 vector of the change in ipsilateral arm volumes at 5 years from 
baseline,  
 CiVcon  be a n*1 vector of the change in contralateral arm volumes at 5 years 
from baseline,  
 Sn is a n*1 vector of 1's and 0's, 1 indicating a positive sentinel node biopsy 
results and 0 otherwise,  
 β0 , β1 and β2 are the regression coefficients which are to be estimated,  
 Xt is a n*1 vector of 1's and 0's  designating the allocated treatment arm 
(1=SNBM)   
 XVips is a n*1 vector of the ipsilateral arm volumes at baseline,  
 XCon is a n*1 vector of the contralteral arm volumes at baseline,  
 XCiVcon is a n*1 vector of the CiV in the contralteral arm,  
 ϵ is a n*1 vector of standard normally errors.  
 
Model 1: The regression model for Vips at 5 years adjusted for treatment can be written 
as 
1.1 
V ips=β0+ β1 X t + ϵ  
Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have 
1.2 
E (V ips | X t=1)=β0+ β1  
and 
1.3 
E (V ips | X t=0)=β0  
From Table 4 the expected 5 year arm volume for the ipsilateral limb in the RAC group 
is 2.59, thus from equation 1.3 we have β0 = 2.59.  
The mean vector and covariance matrix for the SNBM group was randomly given by 
that of the RAC group with probability π. By taking the sum of the expectation of 
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ipsilateral arm volume in the SNBM group over the disjoint union of the events Sn=1 
and Sn=0, and recalling that the expected 5 year arm volume for the ipsilateral limb in 
the SNBM group is 2.59 and 2.56 given a positive sentinel node or negative SNB 
respectively; the expected 5 year volume for the ipsilateral limb in the SNBM group is 
then 
1.4 
E (V ips | X t=1)
= E(V ips | X t=1, S n=1) P (S n=1) + E (V ips | X t=1, S n=0) P (S n=0)
= 2.59π+2.56(1−π)  
Subtracting equation 1.3 from 1.2 gives 
1.5 
E (V ips | X t=1)−E (V ips |X t=0)= β1  
the left hand side (LHS) of 1.5 is 
1.6 2.59π+2.56(1−π)−2.59 =(2.56−2.59)(1−π)  
thus β1 = -0.03(1-π).  
Model 2: for the model Vips adjusted for treatment and baseline ipsilateral arm volume 
write  
2.1 
V ips=β0+ β1 X t + β2 X Vips + ϵ  
Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have 
2.2 
E (V ips | X t=1)=β0+ β1 + β2 E (X Vips | X t=1)  
and 
2.3 
E (V ips | X t=0)=β0 + β2E (X Vips |X t=0)  
Note that from the Table 4, the expected baseline ipsilateral arm volume is 2.45 
respectively in both treatment groups then subtracting equation 2.3 from 2.2 gives 
2.4 
E (V ips | X t=1)−E (V ips |X t=0)= β1  
using result 1.5 and 1.6 we have the treatment effect β1 = -0.03(1-π).  
Model 3: CiVips adjusted for treatment write 
3.1 
CiV ips=β0+ β1 X t + ϵ  
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Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have 
3.2 
E (CiV ips | X t=1)=β0+ β1  
and 
3.3 
E (CiV ips | X t=0)=β0  
Subtracting equation 3.3 from 3.2 gives 
3.4 
E (CiV ips | X t=1)−E (CiV ips | X t=0) =β1  
Looking at the 2 parts of the LHS of equation 3.4 separately and note that the CiVips is 
given by the difference in volumes between baseline and 5 years the expected CiVips in 
the RAC group is given by 
3.5 
E (CiV ips | X t=0)
= E(V ips−X ips | X t=0)
= E(V ips | X t=0)−E (X ips | X t=0)
= 2.59−2.45  
The expected CiVips in the SNBM group  
3.6 
E (CiV ips | X t=1)= E (V ips | X t=1)−E (X ips |X t=1)  
The first part of the right hand side (RHS) of the equation is given by the results 1.4, 
that is 2.59π +2.56(1-π). The second part of then RHS of 3.6 gives 
3.7 
E (X ips | X t=1)
= E(X ips | X t=1, Sn=1) ' P (S n=1)+E (X ips |X t=1, S n=0) ' P (S n=0)
= 2.45π+2.45(1−π)  
Substituting 1.4 and 3.7 into 3.6 we have 
3.8 
E (CiV ips | X t=1) = 2.59π+2.56(1−π)−(2.45π+2.45(1−π))
 = 2.59π+2.56(1−π)−2.45
. 
Using results 3.8 and 3.5 it follows that the estimated treatment effect β1 is 
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3.9 
β1
= E (CiV ips | X t=1)−E (CiV ips | X t=0)
=2.59π+2.56(1−π)−2.45−(2.59−2.45)
=2.59π+2.56(1−π)−2.59
=−0.03(1−π)  
thus the treatment effect β1 = -0.03(1-π). 
Model 4: for CiVips adjusted for treatment and baseline Vips write 
CiV ips=β0+ β1 X t + β2 X Vips + ϵ  
Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have 
E (CiV ips | X t=1)=β0+ β1 + β2 E (X Vips | X t=1)    
and 
E (CiV ips | X t=0)=β0 + β2E (X Vips |X t=1) .  
Taking the difference of both and noting that  
E (X Vips | X t=1)=E (X Vips |X t=0)  
we have 
E (CiV ips | X t=1)−E (CiV ips | X t=0)= β1  
which from the results of equation 3.9 we know the treatment effect β1 = -0.03(1-π). 
Model 5: for CiVips adjusted for treatment and CiVcon write 
CiV ips=β0+ β1 X t + β2 XCiVcon + ϵ
 
Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have  
E (CiV ips | X t=1)=β0+ β1 + β2 E (XCiVcon |X t=1)    
and 
E (CiV ips | X t=0)=β0 + β2E (X CiVcon | X t=1) .  
Taking the difference of both we have 
E (CiV ips | X t=1)−E (CiV ips | X t=0)=β1−β2(E(X CiVcon |X t=1)−E (XCiVcon |X t=0))  
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Note that the multiplicand of β2 is equal to zero as the baseline and 5 year contralateral 
arm volumes for the RAC group and SNBM group are respectively 2.45 and 2.53.  
Then from the results of equation 3.9 we have the treatment effect β1 = -0.03(1-π). 
Model 6: δCiV adjusted for treatment. 
δCiV ips=β0+ β1 X t + ϵ  
Taking expectation of both sides and setting Xt to be equal to '1' or '0' we have 
E (δCiV ips | X t=1)=β0+ β1  
and  
E (δCiV ips | X t=0)=β0  
Taking the difference of both we have 
E (δCiV ips | X t=1)−E (δCiV ips | X t=0)=β1  
Looking at the expected δCiV in the RAC group we have 
E (δCiV ips | X t=0)
= E(CiV ips−CiV con | X t=0)
= E(CiV ips | X t=0)−E(CiV con |X t=0)  
Similarly in the SNBM group 
E (δCiV ips | X t=0)= E (CiV ips | X t=1)−E (CiV con |X t=1)  
β1 the difference of the expectations is then  
E (CiV ips | X t=1)−E (CiV con |X t=1)−(E (CiV ips | X t=0)−E (CiV con |X t=0))  
Note that the differences of the expectation for the contralateral arm between the 
treatment groups 
E (CiV con | X t=1)−E (CiV con |X t=0)=0  
since the baseline and 5 year contralateral arm volumes for the RAC group and SNBM 
group are respectively 2.45 and 2.53. β1 the difference of the expectations reduces to 
β1=E (CiV ips | X t=1)−E (CiV ips | X t=0)  
which from the results of equation 3.9 we have the treatment effect β1 = -0.03(1-π). 
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The various simulations undertaken vary the 5 year arm volume in the ipsilateral limb 
while that of the contralateral stays fixed. Denote the mean of 5 year arm volume in the 
ipsilateral given a negative SNB as μips and the 5 year arm volume in the contralateral 
limb as μcon, and their difference as μ. Then the RHS of 1.6 is then ( μips-μcon)(1-π)=μ(1-
π).  
In the general case we have the estimated treatment effect β1 = μ(1-π).  
Simulation experiment results 
Table 11:Model fit statistics for various scenarios 
Covariance moderate 
 Model βtreat Var(βtreat) CI treat bias MSE R
2
 Adj R
2
 AIC 
π=0.3, 1:1 Treatment allocation       
µ=0.0 1 0.002 0.001582 (-0.074 ,0.078) 0.002 0.395 0.001 0.000 -928 
2 0.000 0.000485 (-0.042 ,0.044) 0.000 0.123 0.689 0.688 -2094 
3 0.000 0.000491 (-0.041 ,0.044) 0.000 0.125 0.001 -0.000 -2079 
4 0.000 0.000485 (-0.042 ,0.044) 0.000 0.123 0.018 0.016 -2094 
5 0.001 0.000160 (-0.024 ,0.025) 0.001 0.040 0.679 0.678 -3213 
6 0.001 0.000181 (-0.025 ,0.027) 0.001 0.045 0.001 0.000 -3101 
µ=-0.03 1 -0.029 0.001605 (-0.107 ,0.051) -0.000 0.395 0.002 0.001 -929 
2 -0.030 0.000486 (-0.073 ,0.013) -0.001 0.123 0.689 0.688 -2094 
3 -0.030 0.000491 (-0.072 ,0.013) -0.001 0.125 0.003 0.002 -2079 
4 -0.030 0.000486 (-0.073 ,0.013) -0.001 0.123 0.020 0.018 -2094 
5 -0.030 0.000160 (-0.056 ,-0.005) -0.001 0.040 0.679 0.678 -3212 
6 -0.030 0.000188 (-0.057 ,-0.005) -0.001 0.045 0.006 0.005 -3100 
µ=-0.06 1 -0.060 0.001670 (-0.135 ,0.020) -0.001 0.396 0.003 0.002 -926 
2 -0.061 0.000545 (-0.108 ,-0.016) -0.002 0.123 0.690 0.689 -2092 
3 -0.061 0.000549 (-0.109 ,-0.017) -0.002 0.125 0.008 0.007 -2078 
4 -0.061 0.000545 (-0.108 ,-0.016) -0.002 0.123 0.024 0.023 -2092 
5 -0.061 0.000171 (-0.085 ,-0.035) -0.002 0.040 0.681 0.681 -3212 
6 -0.061 0.000185 (-0.086 ,-0.033) -0.002 0.045 0.021 0.020 -3101 
1:1 Treatment allocation, μ=-0.03      
π=0.1 1 -0.032 0.001620 (-0.107 ,0.052) -0.002 0.395 0.002 0.001 -927 
 2 -0.030 0.000484 (-0.074 ,0.013) -0.001 0.123 0.688 0.688 -2091 
 3 -0.030 0.000486 (-0.072 ,0.012) -0.001 0.125 0.003 0.002 -2076 
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 Model βtreat Var(βtreat) CI treat bias MSE R
2
 Adj R
2
 AIC 
 4 -0.030 0.000484 (-0.074 ,0.013) -0.001 0.123 0.019 0.017 -2091 
 5 -0.030 0.000159 (-0.053 ,-0.004) 0.000 0.040 0.679 0.679 -3210 
 6 -0.029 0.000174 (-0.054 ,-0.003) 0.000 0.045 0.006 0.005 -3098 
π=0.3 1 -0.028 0.001545 (-0.101 ,0.050) 0.001 0.394 0.001 0.000 -930 
 2 -0.030 0.000502 (-0.072 ,0.014) -0.000 0.123 0.689 0.688 -2095 
 3 -0.030 0.000512 (-0.073 ,0.014) -0.001 0.125 0.003 0.002 -2080 
 4 -0.030 0.000502 (-0.072 ,0.014) -0.000 0.123 0.020 0.018 -2095 
 5 -0.030 0.000151 (-0.054 ,-0.006) -0.001 0.040 0.679 0.679 -3214 
 6 -0.030 0.000167 (-0.056 ,-0.005) -0.001 0.045 0.006 0.005 -3103 
π=0.5 1 -0.031 0.001686 (-0.111 ,0.047) -0.002 0.395 0.002 0.001 -927 
 2 -0.031 0.000471 (-0.076 ,0.011) -0.002 0.123 0.689 0.688 -2092 
 3 -0.031 0.000471 (-0.077 ,0.009) -0.002 0.125 0.003 0.002 -2078 
 4 -0.031 0.000471 (-0.076 ,0.011) -0.002 0.123 0.019 0.017 -2092 
 5 -0.030 0.000156 (-0.056 ,-0.006) -0.002 0.040 0.679 0.679 -3211 
 6 -0.030 0.000176 (-0.057 ,-0.004) -0.002 0.045 0.006 0.005 -3099 
π=0.3, μ=-0.03      
Rnd=1:2 1 -0.033 0.001828 (-0.118 ,0.050) -0.004 0.390 0.002 0.001 -941 
 2 -0.031 0.000618 (-0.081 ,0.017) -0.002 0.115 0.705 0.705 -2160 
 3 -0.031 0.000617 (-0.081 ,0.017) -0.002 0.117 0.003 0.002 -2146 
 4 -0.031 0.000618 (-0.081 ,0.017) -0.002 0.115 0.019 0.017 -2160 
 5 -0.031 0.000216 (-0.060 ,-0.001) -0.002 0.034 0.706 0.705 -3366 
 6 -0.031 0.000231 (-0.060 ,0.001) -0.001 0.040 0.006 0.005 -3219 
 
Covariance week 
 Model βtreat Var(βtreat) CI treat bias MSE R
2
 Adj R
2
 AIC 
π=0.3, 1:1 Treatment allocation       
µ=0.00 1 -0.000 0.000641 (-0.051 ,0.046) -0.000 0.158 0.001 0.000 -1842 
 2 -0.000 0.000216 (-0.030 ,0.028) -0.000 0.049 0.689 0.688 -3007 
 3 -0.000 0.000218 (-0.031 ,0.028) -0.000 0.050 0.001 0.000 -2993 
 4 -0.000 0.000216 (-0.030 ,0.028) -0.000 0.049 0.018 0.016 -3007 
 5 -0.000 0.000068 (-0.017 ,0.015) -0.000 0.016 0.679 0.678 -4127 
 6 0.000 0.000075 (-0.017 ,0.017) 0.000 0.018 0.001 0.000 -4016 
µ=-0.03 1 -0.030 0.000582 (-0.078 ,0.019) -0.001 0.158 0.002 0.001 -1845 
 2 -0.029 0.000203 (-0.056 ,-0.001) -0.000 0.049 0.689 0.688 -3008 
 3 -0.029 0.000208 (-0.057 ,-0.001) -0.000 0.050 0.005 0.004 -2993 
 4 -0.029 0.000203 (-0.056 ,-0.001) -0.000 0.049 0.022 0.020 -3008 
 5 -0.030 0.000063 (-0.045 ,-0.014) -0.001 0.016 0.681 0.680 -4130 
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 Model βtreat Var(βtreat) CI treat bias MSE R
2
 Adj R
2
 AIC 
 6 -0.030 0.000070 (-0.046 ,-0.014) -0.001 0.018 0.013 0.012 -4019 
µ=-0.06 1 -0.059 0.000660 (-0.107 ,-0.011) -0.001 0.158 0.007 0.006 -1845 
 2 -0.059 0.000204 (-0.087 ,-0.032) -0.001 0.049 0.690 0.690 -3009 
 3 -0.059 0.000205 (-0.086 ,-0.032) -0.001 0.050 0.018 0.017 -2994 
 4 -0.059 0.000204 (-0.087 ,-0.032) -0.001 0.049 0.035 0.033 -3009 
 5 -0.060 0.000062 (-0.075 ,-0.045) -0.002 0.016 0.685 0.684 -4130 
 6 -0.060 0.000068 (-0.076 ,-0.045) -0.002 0.018 0.049 0.048 -4019 
π=0.3, 1:1 Treatment allocation, μ=-0.03      
π=0.1 1 -0.030 0.000625 (-0.079 ,0.021) -0.001 0.158 0.002 0.001 -1843 
 2 -0.030 0.000192 (-0.058 ,-0.004) -0.001 0.049 0.690 0.689 -3010 
 3 -0.030 0.000195 (-0.058 ,-0.003) -0.001 0.050 0.006 0.005 -2995 
 4 -0.030 0.000192 (-0.058 ,-0.004) -0.001 0.049 0.022 0.020 -3010 
 5 -0.030 0.000064 (-0.046 ,-0.014) -0.001 0.016 0.681 0.680 -4130 
 6 -0.030 0.000072 (-0.047 ,-0.013) -0.001 0.018 0.014 0.013 -4018 
π=0.3 1 -0.030 0.000649 (-0.077 ,0.022) -0.001 0.158 0.002 0.001 -1844 
 2 -0.030 0.000204 (-0.057 ,-0.003) -0.001 0.049 0.689 0.689 -3010 
 3 -0.030 0.000205 (-0.057 ,-0.003) -0.001 0.050 0.006 0.005 -2995 
 4 -0.030 0.000204 (-0.057 ,-0.003) -0.001 0.049 0.022 0.020 -3010 
 5 -0.030 0.000067 (-0.047 ,-0.015) -0.001 0.016 0.679 0.678 -4125 
π=0.3 6 -0.030 0.000074 (-0.047 ,-0.014) -0.001 0.018 0.014 0.013 -4013 
π=0.5 1 -0.029 0.000652 (-0.078 ,0.024) -0.001 0.158 0.002 0.001 -1844 
 2 -0.030 0.000195 (-0.057 ,-0.003) -0.002 0.049 0.689 0.688 -3009 
 3 -0.030 0.000199 (-0.057 ,-0.003) -0.002 0.050 0.006 0.005 -2994 
 4 -0.030 0.000195 (-0.057 ,-0.003) -0.002 0.049 0.022 0.020 -3009 
 5 -0.030 0.000063 (-0.045 ,-0.015) -0.001 0.016 0.680 0.680 -4128 
 6 -0.030 0.000072 (-0.046 ,-0.014) -0.001 0.018 0.013 0.012 -4016 
π=0.3, μ=-0.03      
Rnd=1:2 1 -0.030 0.000750 (-0.083 ,0.025) -0.001 0.155 0.002 0.001 -1860 
 2 -0.030 0.000243 (-0.061 ,0.000) -0.001 0.046 0.705 0.705 -3079 
 3 -0.030 0.000246 (-0.061 ,0.001) -0.000 0.047 0.005 0.004 -3065 
 4 -0.030 0.000243 (-0.061 ,0.000) -0.001 0.046 0.021 0.019 -3079 
 5 -0.030 0.000083 (-0.048 ,-0.013) -0.001 0.014 0.706 0.705 -4283 
 6 -0.030 0.000087 (-0.049 ,-0.013) -0.001 0.016 0.014 0.013 -4136 
 
Covariance high 
 Model βtreat Var(βtreat) CI treat bias MSE R2 Adj R2 AIC 
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 Model βtreat Var(βtreat) CI treat bias MSE R2 Adj R2 AIC 
π=0.3, 1:1 Treatment allocation      
µ=0.00 1 0.003 0.003332 (-0.112 ,0.117) 0.003 0.888 0.001 -0.000 -117 
 2 -0.000 0.001024 (-0.066 ,0.064) -0.000 0.277 0.689 0.688 -1283 
 3 -0.001 0.001048 (-0.065 ,0.066) -0.001 0.281 0.001 -0.000 -1268 
 4 -0.000 0.001024 (-0.066 ,0.064) -0.000 0.277 0.018 0.016 -1283 
 5 0.000 0.000344 (-0.036 ,0.036) 0.000 0.091 0.678 0.678 -2400 
 6 0.001 0.000394 (-0.039 ,0.039) 0.001 0.101 0.001 -0.000 -2288 
µ=-0.03 1 -0.028 0.003644 (-0.146 ,0.089) 0.002 0.888 0.001 0.000 -118 
 2 -0.030 0.001097 (-0.094 ,0.035) -0.001 0.277 0.689 0.688 -1283 
 3 -0.030 0.001123 (-0.095 ,0.034) -0.001 0.281 0.002 0.001 -1268 
 4 -0.030 0.001097 (-0.094 ,0.035) -0.001 0.277 0.019 0.017 -1283 
 5 -0.029 0.000383 (-0.067 ,0.009) -0.000 0.091 0.678 0.678 -2399 
 6 -0.029 0.000426 (-0.067 ,0.012) -0.000 0.102 0.003 0.002 -2287 
µ=-0.06 1 -0.057 0.003230 (-0.160 ,0.054) 0.001 0.887 0.002 0.001 -119 
 2 -0.059 0.001069 (-0.124 ,0.007) -0.001 0.276 0.689 0.688 -1284 
 3 -0.059 0.001104 (-0.125 ,0.008) -0.001 0.281 0.004 0.003 -1269 
 4 -0.059 0.001069 (-0.124 ,0.007) -0.001 0.276 0.021 0.019 -1284 
 5 -0.060 0.000345 (-0.095 ,-0.022) -0.001 0.090 0.680 0.680 -2405 
 6 -0.060 0.000398 (-0.099 ,-0.021) -0.001 0.101 0.010 0.009 -2292 
1:1 Treatment allocation, μ=-0.03      
π=0.1 1 -0.029 0.003502 (-0.148 ,0.092) 0.001 0.888 0.001 0.000 -118 
 2 -0.031 0.001121 (-0.094 ,0.038) -0.001 0.276 0.689 0.689 -1285 
 3 -0.031 0.001151 (-0.093 ,0.038) -0.001 0.280 0.002 0.001 -1270 
 4 -0.031 0.001121 (-0.094 ,0.038) -0.001 0.276 0.018 0.016 -1285 
 5 -0.031 0.000336 (-0.067 ,0.005) -0.001 0.090 0.678 0.678 -2402 
 6 -0.031 0.000379 (-0.070 ,0.007) -0.001 0.101 0.003 0.002 -2289 
π=0.3 1 -0.031 0.003722 (-0.150 ,0.093) -0.002 0.889 0.001 0.000 -117 
 2 -0.031 0.001117 (-0.096 ,0.034) -0.002 0.278 0.688 0.687 -1279 
 3 -0.031 0.001115 (-0.097 ,0.035) -0.002 0.282 0.002 0.001 -1264 
 4 -0.031 0.001117 (-0.096 ,0.034) -0.002 0.278 0.019 0.017 -1279 
 5 -0.031 0.000368 (-0.069 ,0.007) -0.001 0.090 0.680 0.679 -2401 
 6 -0.031 0.000410 (-0.072 ,0.009) -0.001 0.101 0.003 0.002 -2290 
π=0.5 1 -0.029 0.003748 (-0.149 ,0.088) -0.001 0.889 0.001 0.000 -117 
 2 -0.031 0.001089 (-0.096 ,0.032) -0.002 0.277 0.689 0.688 -1282 
 3 -0.031 0.001101 (-0.095 ,0.035) -0.002 0.281 0.002 0.001 -1267 
 4 -0.031 0.001089 (-0.096 ,0.032) -0.002 0.277 0.019 0.017 -1282 
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 Model βtreat Var(βtreat) CI treat bias MSE R2 Adj R2 AIC 
 5 -0.030 0.000367 (-0.069 ,0.006) -0.002 0.090 0.679 0.679 -2402 
 6 -0.030 0.000434 (-0.071 ,0.009) -0.001 0.101 0.003 0.002 -2291 
π=0.3, μ=-0.03      
Rnd=1:2 1 -0.027 0.003958 (-0.145 ,0.097) 0.002 0.877 0.001 0.000 -130 
 2 -0.029 0.001271 (-0.101 ,0.041) 0.000 0.257 0.707 0.706 -1356 
 3 -0.029 0.001283 (-0.099 ,0.041) -0.000 0.261 0.002 0.001 -1342 
 4 -0.029 0.001271 (-0.101 ,0.041) 0.000 0.257 0.017 0.015 -1356 
 5 -0.030 0.000455 (-0.071 ,0.012) -0.001 0.077 0.705 0.704 -2560 
 6 -0.030 0.000492 (-0.073 ,0.014) -0.001 0.090 0.003 0.002 -2412 
Model: 
1. Ipsilateral arm volume at 5 yrs adjusted for treatment, 
2. Model 1 + baseline contralateral arm volume, 
3. CiV Ipsilateral arm at 5 yrs adjusted for treatment, 
4. Model 3 + baseline contralateral arm volume, 
5. Model 3 + CiV contralateral arm, 
6. δCiV adjusted for treatment. 
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Diagnostic plots: Final model 
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